N@N

IMRIS appoints Kelly McNeill as Chief Financial Officer

^{Published on 2009-08-25 06:11:51, Last Modified on 2009-08-25 06:11:52 - Market Wire}
 

 WINNIPEG, Aug. 25 /CNW/ - (TSX:IM) - IMRIS Inc. (TSX: IM) ("IMRIS" or the "Company") today announced the appointment of Kelly McNeill as Executive Vice President, Finance and Administration and Chief Financial Officer. Mr. McNeill replaces Ron Sabourin who is retiring after serving as IMRIS's CFO since its founding in 2005. Mr. McNeill, a Chartered Accountant, brings a wealth of experience to IMRIS, having worked in the biotechnology and manufacturing industries as well as in both publicly traded and privately held companies. Most recently, Mr. McNeill held the position of Chief Financial Officer with Resverlogix Corp., a publicly traded biotechnology company. He is a member of the Institute of Chartered Accountants of Alberta and holds a Masters of Accountancy and Bachelor of Commerce (Honours) from the University of Manitoba. "With a strong financial background and significant experience in the biotech and manufacturing sectors, as well as expertise across all aspects of public company finance, Kelly is well suited to contribute to IMRIS's success going forward," said David Graves, President & CEO. "We are very pleased to welcome him to the IMRIS team." "I also want to take this opportunity to recognize the outstanding contribution Ron Sabourin has made to our company and the tremendous role he has played in advancing our business to where we are today," added Mr. Graves. "On behalf of the entire IMRIS team, I would like to thank Ron for his service, and wish him all the best in his retirement." Mr. McNeill will assume his position effective September 21, 2009. About IMRIS IMRIS (TSX: IM) is a global leader in providing fully integrated, advanced surgical imaging solutions. The company's flagship product, IMRISneuro, utilizes patented technology that allows a high field MRI scanner to be moved in to the operating room on demand, providing imaging during the surgical procedure without compromising patient safety. This unique and innovative system has been validated by leading neurosurgeons for use in world-class neuroscience centers. 

For further information: Brad Woods, Director Investor Relations & Corporate Communications, IMRIS Inc., Tel: (204) 480-7094, Email: [ bwoods@imris.com ]